Navigation Links
St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
Date:8/29/2007

A new study shows that loss of Arf gene in presence of BCR-ABL mutation leaves ALL cells vulnerable to the growth-enhancing environment of the bone marrow, helping cells develop immunity to the anti-leukemia drug imatinib

MEMPHIS, Tenn., Aug. 29 /PRNewswire-USNewswire/ -- Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec(TM)), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL). The findings may shed new light on why a small percentage of children with ALL do not benefit from treatment, while more than 90 percent of children treated with the latest therapies survive.

The discovery could also help researchers better understand both the origins of this form of aggressive ALL as well as why it becomes resistant to imatinib; and this may lead to more effective treatments for patients who are not helped by current therapies.

CML and an aggressive form of ALL share the same critical mutation -- the Philadelphia chromosome (Ph). Cells that have this mutation (Ph+ cells) produce a rogue growth-promoting enzyme called BCR-ABL. Now, work by a team headed by Charles J. Sherr, M.D., Ph.D., a Howard Hughes Medical Institute investigator and co-chair of the St. Jude Department of Genetics and Tumor Cell Biology Department, has shown that these two forms of leukemia part company in a crucial respect.

"Many Ph+ ALL cells lack a tumor-suppressor gene called Arf, which is normally present in CML cells at the time the disease is first diagnosed," said Sherr. Stripped of the anti-tumor effects of Arf and nurtured by growth factors produced in the bone marrow, these ALL cells become less responsive to imatinib and more difficult to eliminate. Sherr reasons that the cells' survival advantage increases their opportunity to develop mutations in the BCR-ABL protein, which prompt imatinib resistance.

A report on these results appears in the September 15 issue of "Genes & Development."

"The findings also imply that doctors might identify patients at high risk of failing this treatment by determining whether their leukemia cells lack the Arf gene," said Richard T. Williams, M.D., Ph.D., an assistant member in the St. Jude Department of Oncology and the paper's first author.

This study strongly suggests that a widely held explanation for how leukemias arise is not universally applicable. "This view holds that leukemias arise from rare 'cancer stem cells,' which do not make up the bulk of the tumor, but are the only cells required to regenerate the cancer after treatment," Williams said. "However the new St. Jude study reveals that the combination of BCR-ABL activity and inactivation of Arf are sufficient to generate a uniform population of leukemia-initiating cells -- any one of which can expand and induce rapidly fatal disease."

The other author of the paper was Willem den Besten (St. Jude).

This was supported by funding from Howard Hughes Medical Institute, a Cancer Center Core Grant and ALSAC.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit http://www.stjude.org.


'/>"/>
SOURCE St. Jude Children's Research Hospital
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
2. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
6. Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results
7. Antibiotics Dont Prevent Future Urinary Tract Infections, May Cause Resistance in Future Infections
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Treato , the single ... today that it has been named a Cool Vendor ... Life Sciences, 2016, Stephen Davies , ... on life-science- oriented analytics, algorithms and smart machine technology ... confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 2016  ValGenesis, Inc., the market leader ... today announced that a prominent world provider ... chronic kidney failure has selected ValGenesis Validation ... validation process. The global medical device manufacturer ... manage their validation processes electronically. Upon completion ...
(Date:4/27/2016)... 27 Avril 2016   ... de +5% sur le trimestre, soutenu par une ... Croissance de +16% des ventes aux ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), ... annonce aujourd,hui son chiffre d,affaires pour le premier ...
Breaking Medicine Technology:
(Date:5/2/2016)... Viejo, CA (PRWEB) , ... May 02, 2016 , ... ... in Final Cut Pro X. Pick and choose from a variety of electric styles ... with color swabs. Users can customize shadow, dof blur, three dimensional rotation, and much ...
(Date:5/2/2016)... ... 02, 2016 , ... The Civilian Corps of the U.S. Army Medical Command ... care for its uniformed service members, the retired service members, their families and other ... through May 12th National Nurses Week. It acknowledges the hard work and dedication of ...
(Date:5/2/2016)... DC (PRWEB) , ... May 02, 2016 , ... ... Results and Data Book for the 2016 Main Residency Match® (“the Match”), the ... positions in United States teaching institutions. A record-high 30,750 positions were placed in ...
(Date:5/2/2016)... ... May 02, 2016 , ... MedPro Waste Disposal, LLC (MedPro) is ... MedPro now offers its mail back service for an all-inclusive rate. MedPro Disposal President, ... to provide service to all of the clients in the country who are looking ...
(Date:5/2/2016)... ... 02, 2016 , ... Visceral fat, also known as “deep ... liver and pancreas. If not properly addressed, visceral fat can lead to serious ... Medical Oncology and Palliative Care, warns against the dangers of visceral fat. “Just ...
Breaking Medicine News(10 mins):